In support of its anti-tumor role, lower RIPK3 expression correlates with worsened patient survival in lung cancer [12], chronic lymphocytic leukemia [13], colon cancer [14], malignant mesothelioma [15], and breast cancer [16]. The gene discussed is RIPK3; the disease is neoplasm.